Alphamab Oncology (09966.HK) Stock Price, Chart, News and AI analysis

Q: Who is the CEO of Alphamab Oncology?

Dr. Ting Xu is the Executive Chairman of the Board of Alphamab Oncology, joining the firm since 2018.

Q: What is the price performance of ALPHAMAB-B stock?

The current price of ALPHAMAB-B is $9.16, it has decreased 0.43% in the last trading day.

Q: What are the primary business themes or industries for Alphamab Oncology?

Alphamab Oncology belongs to Biotechnology industry and the sector is Health Care

Q: What is Alphamab Oncology market cap?

Alphamab Oncology's current market cap is $8.8B

Home

Stock

09966.HK

ALPHAMAB-B (09966.HK)

Alphamab Oncology

HK$9.16

-0.43%

$-0.03

CLOSED_MARKET: Feb 11, 16:00:00 HKT

Key Stats

Prev.Close

$9.12

Open

$9.2

Day's Range

$9 - $9.28

52 week range

$3.72 - $15.75

Volume

974.0K

Avg.Volume

1.5M

EPS (TTM)

0.27

Dividend yield

Market Cap

$8.8B

What is ALPHAMAB-B?

Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu and currently employs 484 full-time employees. The company went IPO on 2019-12-12. The Company’s in-house pipeline consists of antibody-drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s product pipeline includes KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), JSKN016(HER3/TROP2 bispecific antibody ADC), JSKN033(subcutaneous co-formulation of JSKN003 and KN035), used for indications such as 1L sq NSCLC, 1L HER2+ BC, 1L biliary track cancer, advanced solid tumors, HER2-expressing solid tumors and others.



Features

AI Copilot for Stock & Crypto

Resources